



## Seer Reports First Quarter 2021 Financial Results

May 10, 2021

*Second Phase of Commercialization Advances with the Addition of Multiple Limited Release Customers*

REDWOOD CITY, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the first quarter ended March 31, 2021.

"I am so incredibly proud of and amazed by our team for the progress we have made this quarter," said Omid Farokhzad, Chair and Chief Executive Officer. "Unbiased, deep, rapid proteomics at scale will pave the way for broad-scale and novel biological insight – with incredible impact across science and medicine. We look forward to continuing to build our commercial momentum throughout 2021 as we bring the next phase in omics to labs around the globe."

### Recent Highlights

- Advanced phase two of our three-phase commercial plan by signing agreements with multiple Limited Release customers
- Completed installation at Salk Institute, bringing total number of active collaboration sites to four
- OHSU Knight Cancer Institute and the Broad Institute successfully completed their initial pilot studies and are progressing toward larger-scale follow-on studies
- Strengthened leadership team with the addition of Kenny Ross as VP Operations and Quality
- Doubled the size of Redwood City headquarters with a new lease to support growing organization

### First Quarter 2021 Financial Results

Revenue was \$62,000 for the three months ended March 31, 2021, as compared to \$177,000 for the three months ended March 31, 2020. The decrease was due to less activity associated with our Small Business Innovation Research grant from the NIH.

Operating expenses were \$16.6 million for the first quarter of 2021, as compared to \$6.0 million for the corresponding prior year period. The increase in expenses was driven by higher employee compensation costs and other expenses related to being a publicly traded company, as well as an increase in product development expenses related to our Proteograph Product Suite.

Net loss was \$16.4 million for the first quarter of 2021, as compared to \$5.5 million for the corresponding prior year period.

Cash, cash equivalents and investments were approximately \$531 million as of March 31, 2021.

### Webcast Information

Seer will host a conference call to discuss the first quarter 2021 financial results on Monday, May 10, 2021 at 1:30 pm Pacific Time / 4:30 pm Eastern Time. A webcast of the conference call can be accessed at <http://investor.seer.bio>. The webcast will be archived and available for replay for at least 90 days after the event.

### About Seer

Seer is a life sciences company developing transformative products that open up a new gateway to the proteome. Seer is commercializing its Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy-to-use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be adopted by nearly any lab. Seer's Proteograph Product Suite is for research use only and is not intended for diagnostic procedures.

For more information, please visit [www.seer.bio](http://www.seer.bio).

### Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on the Company's beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements, including but not limited to statements regarding our timing and ability to enable unbiased, deep and rapid proteomics available at scale. These and other risks are described more fully in the Company's filings with the Securities and Exchange Commission ("SEC"), including the Company's Quarterly Report on Form 10-Q, to be filed with the SEC on May 10, 2021, and other documents the Company subsequently files with the SEC from time to time. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Investor Contact:

Carrie Mendivil  
[investor@seer.bio](mailto:investor@seer.bio)

Media Contact:  
Karen Possemato  
[pr@seer.bio](mailto:pr@seer.bio)

**Seer, Inc.**  
**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**  
(In thousands, except share and per share amounts)  
(unaudited)

	Three Months Ended March 31,	
	2021	2020
Revenue	\$ 62	\$ 177
Operating expenses:		
Research and development	6,227	4,222
Selling, general and administrative	10,333	1,780
Total operating expenses	16,560	6,002
Loss from operations	(16,498)	(5,825)
Other income (expense):		
Interest income	69	332
Net loss	\$ (16,429)	\$ (5,493)
Net loss per share attributable to common stockholders, basic and diluted	\$ (0.27)	\$ (0.61)
Weighted-average common shares outstanding, basic and diluted	59,887,842	8,944,284

**Seer, Inc.**  
**CONDENSED CONSOLIDATED BALANCE SHEETS**  
(in thousands)  
(unaudited)

	March 31,	
	2021	2020
<b>ASSETS</b>		
Current assets:		
Cash and cash equivalents	\$ 445,763	\$ 333,585
Investments	85,379	98,278
Inventory	1,541	551
Other receivables	412	163
Other receivables, related parties	101	99
Prepaid expenses and other current assets	3,041	452
Total current assets	536,237	433,128
Property and equipment, net	8,682	8,441
Restricted cash	343	343
Other assets	377	407
TOTAL ASSETS	\$ 545,639	\$ 442,319
<b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>		
Current liabilities:		
Accounts payable	\$ 1,933	\$ 2,115
Accrued expenses	5,021	5,543
Deferred revenue	256	250
Deferred rent, current	186	186
Total current liabilities	7,396	8,094
Deferred rent, net of current portion	1,884	1,899
Other noncurrent liabilities	589	717
Total liabilities	9,869	10,710
Commitments (Note 10)		
Stockholders' equity:		
Preferred stock	—	—

Common stock	1	1
Additional paid-in capital	607,531	486,915
Accumulated other comprehensive income	28	54
Accumulated deficit	(71,790)	(55,361)
Total stockholders' equity	<u>535,770</u>	<u>431,609</u>
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	<u>\$ 545,639</u>	<u>\$ 442,319</u>